Zuellig Pharma Expands Lundbeck Partnership for Neuro-Psychiatric Solutions
This expanded partnership is crucial for improving access to specialized neuro-psychiatric treatments across Asia, a region with significant unmet needs in mental health.
Expanded partnership with Lundbeck to support commercialization of neuro-psychiatric health solutions in Asia.
Zuellig Pharma has expanded its partnership with Lundbeck to enhance the commercialization of neuro-psychiatric health solutions across Asia. This collaboration will leverage Zuellig Pharma's extensive distribution network and market expertise to bring innovative treatments for neurological and psychiatric conditions to a wider patient population. The expanded partnership aims to improve access to specialized healthcare solutions in the region.
This expanded partnership is crucial for improving access to specialized neuro-psychiatric treatments across Asia, a region with significant unmet needs in mental health. By combining Lundbeck's innovative therapies with Zuellig Pharma's robust commercialization capabilities, more patients will benefit from advanced healthcare solutions, addressing a critical public health challenge and fostering better patient outcomes.
The expanded partnership directly addresses the growing need for neuro-psychiatric health solutions in APAC, leveraging Zuellig Pharma's regional reach to improve access to specialized treatments for a significant patient population.
Where this signal fits in the broader landscape.
https://www.zuelligpharma.com/news-insights/Zuellig-Pharma-expands-partnership-with-Lundbeck-to-support-commercialization-of-neuro-psychiatric-health-solutions-in-Asia
Read Full SourceGet curated intelligence delivered to your inbox. No spam, unsubscribe anytime.
Sign in to save notes on signals.
Sign In